Rezultati - Bernaards, Coen
- Showing 1 - 7 results of 7
-
1
-
2
-
3
Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies od Chen, Ya-Chi, Bernaards, Coen, Kulkarni, Rohit, Moreira, Sebastian, Zhu, Yonghong, Chan, Anna, Badman, Ethan, Ackrill, Andrew, Thommes, James, Smith, Patrick F
Izdano 2014Text -
4
Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device od Varunok, Peter, Lawitz, Eric, Beavers, Kimberly L, Matusow, Gary, Leong, Ruby, Lambert, Nathalie, Bernaards, Coen, Solsky, Jonathan, Brennan, Barbara J, Wat, Cynthia, Bertasso, Anne
Izdano 2011Text -
5
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2) od Peters, Solange, Galle, Peter R., Bernaards, Coen A., Ballinger, Marcus, Bruno, René, Quarmby, Valerie, Ruppel, Jane, Vilimovskij, Alexandr, Wu, Benjamin, Sternheim, Nitzan, Reck, Martin
Izdano 2021Text -
6
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1) od Wu, Benjamin, Sternheim, Nitzan, Agarwal, Priya, Suchomel, Julia, Vadhavkar, Shweta, Bruno, Rene, Ballinger, Marcus, Bernaards, Coen A., Chan, Phyllis, Ruppel, Jane, Jin, Jin, Girish, Sandhya, Joshi, Amita, Quarmby, Valerie
Izdano 2021Text -
7
Pharmacokinetic Analysis of Irinotecan Plus Bevacizumab in Patients with Advanced Solid Tumors od Denlinger, Crystal S., Blanchard, Rebecca, Xu, Lu, Bernaards, Coen, Litwin, Samuel, Spittle, Cynthia, Berg, Daniel J., McLaughlin, Susan, Redlinger, Maryann, Dorr, Andrew, Hambleton, Julie, Holden, Scott, Kearns, Anne, Kenkare-Mitra, Sara, Lum, Bert, Meropol, Neal J., O'Dwyer, Peter J.
Izdano 2009Text